Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study (ISO-CC-007) in metastatic colorectal cancer (mCRC) will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, to be held from September 27 to October 1, 2019, in Barcelona, Spain.Dr. Roger Tell, chief medical officer of Isofol, said, “The abstract will be presented as a poster and